<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637552/" ref="ordinalpos=2687&amp;ncbi_uid=1747763&amp;link_uid=PMC2637552" image-link="/pmc/articles/PMC2637552/figure/F1/" class="imagepopup">Figure 1.  From: TGF-? <span class="highlight" style="background-color:">signaling</span> alterations and susceptibility to colorectal cancer. </a></div><br /><div class="p4l_captionBody">TGF-β/SMAD signaling pathway. TGF-β (TGFB1, TGFB2 or TGFB3) binds to the type II TGF-β receptor (TGFBR2: R2), which then binds to the type I TGF-β receptor (TGFBR1: R1) and forms a heterodimeric complex in which TGFBR1 kinase becomes activated. SMAD2 and SMAD3 are phosphorylated by activated TGFBR1. Once phosphorylated, they associate with SMAD4 and move to the nucleus where they act as transcription factors.</div></div>